Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study


Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed. The so-called DEVOTE study, involving more than 7,500 patients, demonstrated Tresiba's non-inferiority of major adverse cardiovascular events to rival Sanofi's long-acting insulin Lantus , the Novo statement said.



from Biotech News